SBIR/STTR Research Award
USE OF FAS LIGAND TO SUPPRESS ARTHRITIS
Award amount
$100,010Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GLOBEIMMUNE, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: Preliminary reports by several groups have demonstrated the
potential for Fas ligand-based therapy to prevent transplant rejection, to
treat autoimmune disease, to induce immunological tolerance and to treat
cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune
Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and
Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology
from the University of Colorado. The overall goal of this Phase I SBIR
application is to develop and test in a well-established mouse model of
arthritis, commercially-useful recombinant adenoviral gene therapy vectors
encoding mutated versions of Fas ligand with enhanced therapeutic potential.
These vectors and strategies for their production and application to treat
human rheumatoid arthritis (U.S. Patents Pending) will be licensed to
Pharmaceutical and/or Biotechnology companies for use in filing Investigational
New Drug (IND) Applications with the FDA in anticipation of phase I clinical
trails in humans.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
Technology keywords
Not reported